PubMed · 2022 · 23 citations · 0 references
Life SciencesGeneticsInfectious DiseasesMedical GeneticsMolecular VirologyPharmacogeneticsGenetic RiskGenetic SusceptibilityInfectious Disease SusceptibilityReceptor PolymorphismsGeographical DisparitiesHost-pathogen Susceptibility VariantsSars-cov-2 InfectionSingle-nucleotide VariantsSusceptibility VariationViral Spike Proteins
There is considerable variation in disease severity among patients infected with SARS-CoV-2, the virus that causes COVID-19. Human genetic variation can affect disease outcome, and the coronaviruses SARS-CoV, SARS-CoV-2, and HCoV-NL63 utilize human ACE2 as the receptor to enter cells. We found that several missense ACE2 single-nucleotide variants (SNVs) that showed significantly altered binding with the spike proteins of SARS-CoV, SARS-CoV-2, and NL63-HCoV. We identified an ACE2 SNP, D355N, that restricts the spike protein-ACE2 interaction and consequently has the potential to protect individuals against SARS-CoV-2 infection. Our study highlights that ACE2 polymorphisms could impact human susceptibility to SARS-CoV-2, which may contribute to ethnic and geographical differences in SARS-CoV-2 spread and pathogenicity.